Key result
Vutrisiran cuts mortality and recurrent CV events ~29% in ATTR-CM, with consistent benefit across sexes.
Why the study?
Does subcutaneous vutrisiran reduce the composite of all-cause mortality and recurrent cardiovascular events in patients with wild-type or variant transthyretin cardiac amyloidosis across sexes?
RCT (n=654)
Double-blind
1:1
Does subcutaneous vutrisiran reduce the composite of all-cause mortality and recurrent cardiovascular events in patients with wild-type or variant transthyretin cardiac amyloidosis across sexes?
Answers are grounded in this paper and cite their sources.
Vutrisiran provides consistent therapeutic benefit in reducing mortality and cardiovascular events in both men and women with ATTR-CM, despite phenotypic differences at baseline.
Aims Sex differences in transthyretin cardiac amyloidosis (ATTR-CM) are increasingly recognised; however, women are underrepresented in trials and sex-specific treatment effects remain incompletely understood. We evaluated sex differences in baseline phenotype, outcomes and vutrisiran response in ATTR-CM. Methods HELIOS-B was a phase 3, randomised, double-blind, placebo-controlled trial enrolling patients with wild-type or variant ATTR-CM, randomised 1:1 to receive subcutaneous vutrisiran (25 mg every 12 weeks) or placebo. This prespecified analysis assessed baseline characteristics, efficacy, and safety according to sex. Results Among 654 participants, 49 (7.5%) were women. Variant ATTR-CM was more prevalent in women (42.9% vs 9.1%, p < 0.001). At baseline, women had smaller absolute left ventricular dimensions and wall thicknesses (p < 0.05), but when indexed to body surface area, wall thicknesses were higher. Women demonstrated better systolic function, but worse 6-minute walk distances and quality-of-life scores. Vutrisiran reduced the primary composite endpoint of all-cause mortality and recurrent cardiovascular events in both sexes (women, HR 0.59, 95% CI 0.26–1.30; men, HR 0.71, 95% CI 0.54–0.94; p-interaction = 0.66). Confidence intervals were wide in women, reflecting limited precision from small subgroup size. Mortality reduction was observed in both sexes (HR 0.56, 95% CI 0.14–2.34 in women, HR 0.65, 95% CI 0.46–0.90 in men, p-interaction = 0.91 for all-cause mortality at 42 months). Decline in 6-minute walk distance and quality-of-life scores was attenuated in both sexes, with no statistically detectable sex-specific interaction, and safety outcomes were comparable. Conclusion Women with ATTR-CM demonstrated a distinct baseline phenotype in HELIOS-B. Despite this, vutrisiran showed no statistically detectable heterogeneity of treatment effect by sex within the limits of statistical power, supporting therapeutic benefit across the phenotypic spectrum of ATTR-CM.
No takes yet. Share an insight, caveat, or question.
Mansell et al. (2026) conducted an RCT in Transthyretin cardiac amyloidosis (ATTR-CM) (n=654). Vutrisiran vs. Placebo was evaluated on Composite of all-cause mortality and recurrent cardiovascular events (HR 0.59 (women), HR 0.71 (men), 95% CI 0.26-1.30 (women), 0.54-0.94 (men), p=p-interaction = 0.66). Vutrisiran reduced all-cause mortality and recurrent cardiovascular events in both men and women with ATTR-CM.
Synapse has enriched 10 related papers. Consider them for comparative context: